Metoprolol ameliorates cyclosporine A-induced hypertension and nephrotoxicity in rats

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 6, 2011, Pages 639-646

  El Gowilly, Sahar M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

cyclosporine A; cytokine; endothelium dependent vasodilations; metoprolol; oxidative stress

Indexed keywords

CARBACHOL; CATALASE; CYCLOSPORIN A; MALONALDEHYDE; METOPROLOL; OLIVE OIL; RENIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY FUNCTION; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENOVASCULAR DISEASE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; VASODILATATION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CARBACHOL; CYCLOSPORINE; CYTOKINES; ENDOTHELIUM, VASCULAR; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MALE; METOPROLOL; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 83155172383     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318231166f     Document Type: Article

References (46)

1. Lassila M, Santisteban J, Finckenberg P, et al. Vascular changes in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. J Physiol Pharmacol. 2001;52:21-38. (Pubitemid 32246565)
2. Faulds D, Goa KL, Benflield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953-1040. (Pubitemid 23219075)
3. Nishiyama A, Kobori H, Fukui T, et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension. 2003;42:754-760. (Pubitemid 37237321)
4. Simonis G, Christ T, Bährle SK, et al. Receptor-independent sensitization of the adenylyl cyclase after chronic treatment with cyclosporine A. Naunyn-Schmiedebergs Arch Pharmacol. 2008;378:253-260.
5. El-Mas MM, Mohy El-Din MM, El-gowilly SM, et al. Relative roles of endothelial relaxing factors in cyclosporine-induced impairment of cholinergic and b-adrenergic renal vasodilations. Eur J Pharmacol. 2004; 487:149-158. (Pubitemid 38368992)
6. Shihab FS, Andoh TF, Tanner AM, et al. Role of transforming growth factor-beta 1 in experimental chronic nephropathy. Kidney Int. 1998;49: 141-151.
7. Navarro-Antolín J, Redondo-Horcajo M, Zaragoza C, et al. Role of peroxynitrite in endothelial damage mediated by cyclosporine A. Free Radic Biol Med. 2007;42:394-403. (Pubitemid 46038047)
8. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70:1905-1913. (Pubitemid 44863377)
9. Parving HH, Andersen AR, Smidt UM. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ. 1987;294: 1443-1447. (Pubitemid 17079619)
10. Rudberg S, Osterby R, Bangstad HJ, et al. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type I (insulin-dependent) diabetes mellitus. Diabetologia. 1999;42:589-595. (Pubitemid 29196010)
11. Yasumoto R, Asakawa M, Kakinoki K. Effect of metoprolol in patients with renal hypertension. Hinyokika Kiyo. 1988;34:1669-1673.
12. DiBona GF, Sawin LL. Congestive heart failure effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. Circulation. 1999;100:82-86. (Pubitemid 29297944)
13. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of sub-antihypertensive doses of alpha and beta-blockers. Kidney Int. 2001;60:1309-1323. (Pubitemid 32962590)
14. Padi SS, Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron. 2002;92:685-692.
15. Gibson K, Orij I. Role of metoprolol, b1-adrenoceptor antagonist, thromboxane A2 and nitric oxide in CSA-induced hypertension. Prost Leuk Essent Fatty Acids. 2003;68:233-238.
16. Funovic P, Korda M, Kubant R, et al. Effect of beta-blockers on endothelial function during biological aging: A nano-technological approach. J Cardiovasc Pharmacol. 2008;51:208-215. (Pubitemid 351301483)
17. El-Gowilly SM, Ghazal AR, Gohar EY, et al. Exacerbation by nicotine of the cyclosporine A-induced impairment of beta-adrenoceptor-mediated renal vasodilation in rats. Clin Exp Pharmacol Physiol. 2008;35: 1164-1171.
18. El-Mas MM, Mohy El-Din MM, El-gowilly SM, et al. Regional and endothelial differences in the cyclosporine attenuation of adenosine receptor- mediated vasorelaxations. J Cardiovasc Pharmacol. 2004;43: 562-573. (Pubitemid 39090023)
19. El-Mas MM, El-Din MM, El-Gowilly SM, et al. The a1-adrenergic receptor not the DA1-dopaminergic receptor mediates cyclosporine- SKF38393 renovascular interaction. Can J Physiol Pharmacol. 2005; 83:1129-1136.
20. Moshage H, Kok B, Huizenga JR, et al. Nitrite and nitrate determinations in plasma: A critical evaluation. Clin Chem. 1995;41:892-896.
21. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358. (Pubitemid 9194347)
22. Marklund S, Marklund G. Involvement of superoxide anion radical in autoxidation of pyrogallol and a convenient assay for SOD. Eur J Biochem. 1974;47:469-474.
23. Aebi H. Catalase invitro assay methods. Meth Enzymol. 1984;105: 121-126.
24. Johnson AM. Amino acids, peptides and proteins. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Text Book of Clinical Chemistry and Molecular Diagnosis. 4th ed. Missouri: WB Saunders; 2006:588-589.
25. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation. 2000;70:690-694. (Pubitemid 30659658)
26. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension. 2002;39: 129-134. (Pubitemid 34098101)
27. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 1979;38(Suppl 3):S13-S16.
28. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third generation b-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: A novel mechanism for antihypertensive action. Circulation. 2003;107:2747-2752. (Pubitemid 36667251)
29. Gschwend S, Haug MB, Nierhaus M, et al. Short-term treatment with beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure. Life Sci. 2009;85:431-437.
30. Galle J, Lehmann-Bodem C, Hubner U, et al. CyA and OxLDL cause endothelial dysfunction in isolated arteries through endothelin-mediated stimulation of O(2)(-)formation. Nephrol Dial Transplant. 2000;15: 339-346. (Pubitemid 30116468)
31. Kalaycioglu S, Sinci V, Imren Y, et al. Metoprolol prevents ischemiareperfusion injury by reducing lipid peroxidation. Jpn Circ J. 1999;63: 718-721. (Pubitemid 29436668)
32. Fiordaliso F, De Angelis N, Bai A, et al. Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats. Life Sci. 2007;81:951-959.
33. Prabhu SD, Chandrasekar B, Murray DR, et al. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101:2103-2109. (Pubitemid 30233176)
34. Lu Y, Li L, Zhao X, et al. Beta blocker metoprolol protects against contractile dysfunction in rats after coronary micro-embolization by regulating expression of myocardial inflammatory cytokines. Life Sci. 2011; 88:1009-1015.
35. Dörge H, Schulz R, Belosjorow S, et al. Coronary microembolization: The role of TNF-a in contractile dysfunction. J Mol Cell Cardiol. 2002; 34:51-62. (Pubitemid 34146395)
36. Salem NA, Salem EA, Maarouf AM, et al. Protective effect of trapidil and L-arginine against renal and hepatic toxicity induced by cyclosporine in rats. Ren Fail. 2010;32:959-968.
37. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity induced insulin resistance. Science. 1996;271:665-668. (Pubitemid 26052915)
38. Shihab FS, Bennett WM, Yi H, et al. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant. 2002; 2:111-119. (Pubitemid 36306789)
39. Baxter CR, Duggin GG, Hall BM, et al. Stimulation of renin release from rat renal cortical slices by cyclosporin A. Res Commun Chem Pathol Pharmacol. 1984;43:417-423. (Pubitemid 14169872)
40. Kurtz A, Della Bruna R, Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int. 1988; 33:947-953.
41. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev.1997;77:75-197.
42. Kopp UC, DiBona GF. Neural regulation of renin secretion. Semin Nephrol. 1997;13:543-551. (Pubitemid 23336192)
43. Münter K, Hergenroder S, Jochims K, et al. Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. J Am Soc Nephrol. 1996;7: 681-686. (Pubitemid 27466000)
44. Sabbatini M, Vitaioli L, Baldoni E, et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Therapeut. 2000;294:948-954. (Pubitemid 30666845)
45. Michel MC, Siegl H, Larson DF, et al. Effects of cyclosporin A on blood pressure and b-adrenoceptor density in spontaneously hypertensive rats. J Hypertens. 1987;5:S125-S127.
46. Leeman M, Vereerstraeten P, Uytdenhoef M, et al. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients. J Cardiovasc Pharmacol. 1993;22:706-710. (Pubitemid 23315374)